miRdetect, a Bremen, Germany-based startup that develops a test method for the detection of testicular cancer, raised a seven-figure sum in seed funding.
Backers High-Tech Gründerfonds, BAB Beteiligungs- und Managementgesellschaft Bremen mbH and a private investor.
Founded in 2016 by Meike Spiekermann and Dr. Nina Winter, miRdetect is advancing a method for the detection of testicular cancer via a novel blood test.
With the test kit, testicular cancer can be diagnosed with high specificity in the patient’s blood using a patented molecular diagnostic procedure. In addition, it makes it possible to monitor the course of therapy and reliably detect a recurrence of the tumor.
The method has the potential to be utilized for the detection of other types of cancer in the future.
Since 2011, Spiekermann and Dr. Winter have been working on the new tumor marker at the University of Bremen. In order to optimize further product development, miRdetect also uses the expertise of urologist Prof. Klaus-Peter Dieckmann, and human geneticist Dr. Gazanfer Belge, who are also both co-founders of the company.